News

Fierce Biotech11h
ASCO: Kite’s CAR-T passes lymphoma safety trial with flying colors
Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...
Fierce Biotech22h
ASCO: Immatics PRAME cell therapy tied to 56% response rate in melanoma study
Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...